Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 3

SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

January 7, 2025

Panelists discuss how afamitresgene autoleucel (afami-cel) demonstrated meaningful clinical activity in SPEARHEAD-1, with manageable cytokine release syndrome as the main safety concern.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

EP. 2: Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

Now Viewing

EP. 3: SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

EP. 4: Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

EP. 5: Key Differences in T-Cell Response Therapy vs CAR T Therapy

EP. 6: Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey

EP. 7: Sequencing Strategies of Afami-Cel With Chemotherapy and Targeted Therapies

EP. 8: Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

EP. 9: Best Practices for HLA and MAGE-A4 Testing

EP. 10: Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

EP. 11: Approaches to First-Line Treatment for Synovial Sarcoma

EP. 12: Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases

EP. 13: Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

EP. 14: Logistical Considerations for Delivering TCR Therapy to Patients

EP. 15: Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

EP. 16: Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

Video content above is prompted by the following:

Briefly review the pivotal SPEARHEAD-1 trial that led to afami-cel’s approval.
Please review study design, key efficacy and safety (Tine et al, CTOS2022).
Please explain the role of targeting MAGE-A4.